Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C20H2Cl4I4O5.2Na |
| Molecular Weight | 1017.636 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
[Na+].[Na+].[O-]C(=O)C1=C(Cl)C(Cl)=C(Cl)C(Cl)=C1C2=C3C=C(I)C(=O)C(I)=C3OC4=C2C=C(I)C([O-])=C4I
InChI
InChIKey=UWBXIFCTIZXXLS-UHFFFAOYSA-L
InChI=1S/C20H4Cl4I4O5.2Na/c21-10-8(9(20(31)32)11(22)13(24)12(10)23)7-3-1-5(25)16(29)14(27)18(3)33-19-4(7)2-6(26)17(30)15(19)28;;/h1-2,29H,(H,31,32);;/q;2*+1/p-2
| Molecular Formula | C20H2Cl4I4O5 |
| Molecular Weight | 971.657 |
| Charge | -2 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
| Molecular Formula | Na |
| Molecular Weight | 22.98976928 |
| Charge | 1 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
Rose bengal sodium (RB) is a small molecule, halogenated xanthene being developed by Provectus Biopharmaceuticals (formerly Provectus Pharmaceuticals). It is commonly used in eye drops to stain damaged conjunctival and corneal cells and thereby identify damage to the eye. The stain is also used in the preparation of Foraminifera for microscopic analysis, allowing the distinction between forms that were alive or dead at the time of collection. A form of rose bengal is also being studied as a treatment for certain cancers and skin conditions. The cancer formulation of the drug, known as PV-10, is currently undergoing clinical trials for melanoma and breast cancer. Recently, interest in RB as a therapeutic cancer treatment has increased due to significant anti-tumor responses with direct tumor injection in human clinical trials for metastatic melanoma. In these patients, there has been the implication that RB may mount a T-cell mediated anti-tumor response and impart antigen-specific responses in distant bystander lesions.
Originator
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: HSV-1, McKrae strain Sources: https://www.ncbi.nlm.nih.gov/pubmed/2821977 |
|||
Target ID: GO:0008219 Sources: https://www.ncbi.nlm.nih.gov/pubmed/28151483 |
|||
Target ID: CHEMBL613825 |
|||
Target ID: CHEMBL2111472 Sources: https://www.ncbi.nlm.nih.gov/pubmed/24405273 |
0.072 µM [IC50] | ||
Target ID: CHEMBL1743316 Sources: https://www.ncbi.nlm.nih.gov/pubmed/24405273 |
0.035 µM [IC50] | ||
Target ID: GO:0002456 |
|||
Target ID: P10408 Gene ID: 944821.0 Gene Symbol: secA Target Organism: Escherichia coli (strain K12) Sources: https://www.ncbi.nlm.nih.gov/pubmed/22354575 |
0.5 µM [IC50] |
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Primary | Unknown Approved UseUnknown |
|||
| Primary | Unknown Approved UseUnknown |
|||
| Primary | Unknown Approved UseUnknown |
|||
| Primary | Unknown Approved UseUnknown |
|||
| Diagnostic | ROBENGATOPE Approved UseRobengatope Injectable is used for the treatment, control, prevention, & improvement of the following diseases, conditions and symptoms:
Diagnostic Agent For Routine Ocular Examinations
Diagnosis Of Superficial Conjunctiva Or Corneal Tissue Change
Diagnosis Of Keratoconjunctivitis Sicca Join 210 Pro Subscribers
Diagnosis Of Keratitis
Diagnosis Of Abrasions Or Corrosions Launch Date1971 |
Funbound
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
33.7% EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/2457477/ |
ROSE BENGAL POTASSIUM serum | Homo sapiens |
||
5% EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/19582268/ |
ROSE BENGAL POTASSIUM plasma | Homo sapiens |
PubMed
| Title | Date | PubMed |
|---|---|---|
| Rose Bengal- and Riboflavin-Mediated Photodynamic Therapy to Inhibit Methicillin-Resistant Staphylococcus aureus Keratitis Isolates. | 2016-06 |
|
| Distance-Dependent Plasmon-Enhanced Singlet Oxygen Production and Emission for Bacterial Inactivation. | 2016-03-02 |
|
| The Potential of Intralesional Rose Bengal to Stimulate T-Cell Mediated Anti-Tumor Responses. | 2015-08 |
|
| Characterization of Rose Bengal binding to sinusoidal and bile canalicular plasma membrane from rat liver. | 1989-01-16 |
Patents
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/24510477
Melanoma: enrolled patients received a single intralesional injection of Rose bengal sodium (PV‐10) into 1–3
target lesions at a dose of 0.5 ml/cc of measured lesion volume.
Route of Administration:
Other
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/1321912
Incubation of isolated sarcolemmal vesicles from canine heart with irradiated rose bengal (150 nM) resulted in 86 +/- 1% inhibition of Na+K(+)-ATPase activity
| Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 18:02:19 GMT 2025
by
admin
on
Mon Mar 31 18:02:19 GMT 2025
|
| Record UNII |
956575SN5L
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Preferred Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
FDA ORPHAN DRUG |
657518
Created by
admin on Mon Mar 31 18:02:19 GMT 2025 , Edited by admin on Mon Mar 31 18:02:19 GMT 2025
|
||
|
WHO-ATC |
S01JA02
Created by
admin on Mon Mar 31 18:02:19 GMT 2025 , Edited by admin on Mon Mar 31 18:02:19 GMT 2025
|
||
|
WHO-VATC |
QS01JA02
Created by
admin on Mon Mar 31 18:02:19 GMT 2025 , Edited by admin on Mon Mar 31 18:02:19 GMT 2025
|
||
|
NCI_THESAURUS |
C461
Created by
admin on Mon Mar 31 18:02:19 GMT 2025 , Edited by admin on Mon Mar 31 18:02:19 GMT 2025
|
||
|
FDA ORPHAN DRUG |
233706
Created by
admin on Mon Mar 31 18:02:19 GMT 2025 , Edited by admin on Mon Mar 31 18:02:19 GMT 2025
|
||
|
FDA ORPHAN DRUG |
670618
Created by
admin on Mon Mar 31 18:02:19 GMT 2025 , Edited by admin on Mon Mar 31 18:02:19 GMT 2025
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
32343
Created by
admin on Mon Mar 31 18:02:19 GMT 2025 , Edited by admin on Mon Mar 31 18:02:19 GMT 2025
|
PRIMARY | |||
|
632-69-9
Created by
admin on Mon Mar 31 18:02:19 GMT 2025 , Edited by admin on Mon Mar 31 18:02:19 GMT 2025
|
PRIMARY | |||
|
1362690
Created by
admin on Mon Mar 31 18:02:19 GMT 2025 , Edited by admin on Mon Mar 31 18:02:19 GMT 2025
|
PRIMARY | RxNorm | ||
|
11874
Created by
admin on Mon Mar 31 18:02:19 GMT 2025 , Edited by admin on Mon Mar 31 18:02:19 GMT 2025
|
PRIMARY | |||
|
956575SN5L
Created by
admin on Mon Mar 31 18:02:19 GMT 2025 , Edited by admin on Mon Mar 31 18:02:19 GMT 2025
|
PRIMARY | |||
|
SUB15149MIG
Created by
admin on Mon Mar 31 18:02:19 GMT 2025 , Edited by admin on Mon Mar 31 18:02:19 GMT 2025
|
PRIMARY | |||
|
100000078666
Created by
admin on Mon Mar 31 18:02:19 GMT 2025 , Edited by admin on Mon Mar 31 18:02:19 GMT 2025
|
PRIMARY | |||
|
211-183-3
Created by
admin on Mon Mar 31 18:02:19 GMT 2025 , Edited by admin on Mon Mar 31 18:02:19 GMT 2025
|
PRIMARY | |||
|
52261
Created by
admin on Mon Mar 31 18:02:19 GMT 2025 , Edited by admin on Mon Mar 31 18:02:19 GMT 2025
|
PRIMARY | |||
|
m9663
Created by
admin on Mon Mar 31 18:02:19 GMT 2025 , Edited by admin on Mon Mar 31 18:02:19 GMT 2025
|
PRIMARY | Merck Index | ||
|
DBSALT001538
Created by
admin on Mon Mar 31 18:02:19 GMT 2025 , Edited by admin on Mon Mar 31 18:02:19 GMT 2025
|
PRIMARY | |||
|
DTXSID4022814
Created by
admin on Mon Mar 31 18:02:19 GMT 2025 , Edited by admin on Mon Mar 31 18:02:19 GMT 2025
|
PRIMARY | |||
|
956575SN5L
Created by
admin on Mon Mar 31 18:02:19 GMT 2025 , Edited by admin on Mon Mar 31 18:02:19 GMT 2025
|
PRIMARY | |||
|
C87723
Created by
admin on Mon Mar 31 18:02:19 GMT 2025 , Edited by admin on Mon Mar 31 18:02:19 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
PARENT -> SALT/SOLVATE |
|